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Abstract
Background: Hypoxia is associated with increased resistance to chemo- and radiation-therapy.
Hyperoxic treatment (hyperbaric oxygen) has previously been shown to potentiate the effect of
some forms of chemotherapy, and this has been ascribed to enhanced cytotoxicity or
neovascularisation. The aim of this study was to elucidate whether hyperoxia also enhances any
actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes
in the interstitium and extracellular matrix.
Methods: One group of tumor bearing rats was exposed to repeated hyperbaric oxygen (HBO)
treatment (2 bar, pO2 = 2 bar, 4 exposures à 90 min), whereas one group was exposed to one
single identical HBO treatment. Animals housed under normal atmosphere (1 bar, pO2 = 0.2 bar)
served as controls. Three doses of 5FU were tested for dose response. Uptake of [3H]-5FU in the
tumor was assessed, with special reference to factors that might have contributed, such as
interstitial fluid pressure (Pif), collagen content, oxygen stress (measured as malondialdehyd levels),
lymphatics and transcapillary transport in the tumors.
Results: The uptake of the cytostatic agent increases immediately after a single HBO treatment
(more than 50%), but not 24 hours after the last repeated HBO treatment. Thus, the uptake is most
likely related to the transient increase in oxygenation in the tumor tissue. Factors like tumor Pif and
collagen content, which decreased significantly in the tumor interstitium after repeated HBO
treatment, was without effect on the drug uptake.
Conclusion: We showed that hyperoxia increases the uptake of [3H]-5FU in DMBA-induced
mammary tumors per se, independently of changes in Pif, oxygen stress, collagen fibril density, or
transendothelial transport alone. The mechanism by which such an uptake occur is still not
elucidated, but it is clearly stimulated by elevated pO2.
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Background
A tumor is comprised of cancer cells as well as stromal
cells (fibroblasts, immune cells) that are embedded in an
extracellular matrix (ECM) and nourished by vasculature.
Because of irregular and tortuous tumor blood vessels
with impaired blood flow and high proliferation rate,
tumors have large hypoxic areas, especially in the central
parts. It is now widely accepted that hypoxia induces
tumor growth and enhances both radiation- and chemo-
resistance of cancer cells [1].
Inefficiency of chemotherapy can partly be explained by
development of multidrug resistance to different chemo-
therapeutic agents. However, the causes of hypoxia-medi-
ated resistance are multifactorial. Some chemotherapeutic
drugs require oxygen to generate free oxygen radicals that
in turn induce cytotoxicity. Genetic and proteomic
changes may have substantial effect, by altering prolifera-
tion kinetics, cell cycle position, inhibiting apoptosis and
regulate angiogenesis and cellular metabolism [2]. How-
ever, drug resistance can also be caused by the inefficient
transport of the anticancer drug into the tumor tissue.
Solid tumors have a pathologically increased interstitial
fluid pressure (Pif) and a dense ECM that make transport
of chemotherapeutic agents difficult [3-7]. Increased Pif
leads to decreased transcapillary transport, and thereby
hinders efficient uptake of chemotherapy [8], while the
fibrotic nature of the dense ECM in solid tumors have
been shown to impede transport of molecules in the
tumor interstitium, and thereby decrease the effect of
cytostatic drugs [9-11]. Since Pif can be lowered and the
structure of the tumor interstitium can be altered, this
could have the potential to enhance the efficiency of drug-
based treatment of solid malignancies.
As hypoxia reduces the response of chemotherapeutic
agents, we aimed to study the effect of enhanced oxygen-
ation on drug-uptake in mammary tumors, by using
hyperbaric oxygen (HBO). HBO increases oxygen tension
and oxygen delivery to tissues independent of haemo-
globin. This pO2 elevation has been shown to last for up
to 60 min post HBO treatment [12]. Because of this, HBO
has previously been used to enhance the pO2 in hypoxic
tumor tissue, to potentiate the effect of radio- and photo-
therapy in both clinical and preclinical trials and also the
effect of some forms of chemotherapy like doxorubicin,
alkylating agents and 5FU [13-16]. This effect has been
ascribed as increased cytotoxicity of the tumor cells to the
chemotherapeutic drug in vitro [16,17] and enhanced neo-
vascularisation in vivo [18]. However, recent studies have
shown reduced vascularisation after HBO treatment in
vivo [19-21].
Therefore, the aim of the present study was to study if
there is an effect of either a single (1) or repeated (4) treat-
ments (each 90 min) of 2 bar pure oxygen on the uptake
of radioactively labelled 5FU in the tumor tissue per se,
and whether this is related to elevated pO2and micro-
environmental factors like Pif, collagen fibrils, transcapil-
lary transport and oxygen stress. We would then be able to
conclude that the HBO enhancement of chemotherapeu-
tic effects, previously shown in the literature, is not only
due to an enhanced sensitisation of the tumor cells.
Methods
Animals and tumor model
Female Sprague-Dawley rats were used. Mammary tumors
(adenocarcinomas) were induced by dimetyl-α-benzan-
tracene (DMBA) dissolved in olive oil and given to the rat
by gavage at the age of 7 weeks at a dose of 16 mg (Møl-
legård, Denmark). The experiments were performed when
the rats were 13-15 weeks old, having reached a body-
weight of approximately 250 g and developed one to three
tumors along the mammary crest. Thus, n is equal to
number of tumors, not the number of rats in these exper-
iments. This was done to minimize the number of ani-
mals used. As tumors are very heterogenous, this was not
considered a problem. We did not perform a power anal-
ysis prior to the experiments. The number of animals in
each group is determined based on previous experience
with rat experiments. However, this is always a general
compromise between experimental accuracy and at the
same time keeping the number of animals as low as pos-
sible. The previous variance in animal experiments has
resulted in the minimum number of animals to n = 5. The
animals were randomly allocated to the treatments
groups, and none were excluded from the treatment pro-
cedure. Malondialdehyde and hydoxyproline experiments
were performed blinded. As the main investigator per-
formed both the HBO treatment and the rest of the fol-
low-up experiments, blinding was difficult to accomplish.
All the experiments were performed in accordance with
recommendations of the Norwegian State Commission
for Laboratory Animals and were approved by the local
ethical committee.
Hyperbaric hyperbaric chamber
A 30 L pressure chamber with an inner diameter of 25 cm,
and an inner length of 65 cm was used. The chamber was
supplied with pure O2, and the oxygen concentration (%)
was monitored continuously by an oxygen meter (NUI,
Bergen, Norway). After reaching 100% O2 within approx-
imately 10 min, the pressure was raised over a period of
approximately 3 min to 2 bar. The 2 bar pure oxygen
atmosphere was maintained for a period of 90 min. To
maintain >97% O2 atmosphere at all times, the chamber
was flushed with pure oxygen for 3-5 min every 10-30 min
depending on the number of animals in the chamber. The
rats were then decompressed over a period of 10 min.BMC Cancer 2009, 9:446 http://www.biomedcentral.com/1471-2407/9/446
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Experimental groups and treatment design
The different experimental groups and their treatment
details are given in Table 1. The repeated HBO treated rats
were exposed to HBO on day 1, 4, 7 and 10, and the fol-
low-up experiments were performed on day 11. The
choice of this treatment protocol is due to a previous
study [20], showing that 4 HBO treatments gave maximal
growth-inhibitory effect. The single HBO treated group
was only exposed to HBO on day 1 and measurements
performed immediately after the exposure.
Dose response of 5FU
We tested 3 different doses of 5FU. Original dose (1.5 mg/
kg), 1/3 (0.5 mg/kg) dose and 3× (4.5 mg/kg) dose 5FU
was injected intraperitonally and tumor size was meas-
ured by a calliper on day 1, 4, 7 and 11, and estimated
according to the formula: V = π/6 (a2·b), where 'a'
denotes the shortest transversal diameter and 'b' the long-
est transversal diameter. Growth was calculated as growth
change compared to day 1 (100%).
Microdialysis
To determine the uptake of radioactively labelled 5FU
([3H]-5FU) (Nycomed Amersham, Buckinghamshire, UK)
into the tumor tissue, microdialysis technique [22] was
used, as modified in our laboratory [23]. After anaesthe-
sia, the femoral vein was cannulated for injection of [3H]-
5FU. One microdialysis probe (CMA/20, Microdialysis
AB, Stockholm, Sweden) was placed in the jugular vein
and one in the tumor. Both probes were connected to a
pump (CMA-100, Microdialysis AB, Stockholm, Sweden)
and the catheters were perfused with saline at a rate of 1
μl/min. The catheter and probes were left to stabilize and
equilibrate for 60 min before sampling of dialysate. Sam-
pling of dialysate from both tumor and plasma started
immediately after injection of 0.2 ml 0.37 Mbq [3H]-5FU
and fractions were collected every 10 min for a total of 70
min. The area under the curve (AUC) for the plasma and
tumor was calculated as the product of counts per 10 min
(cpm) for a total measurement period of 70 min. Trans-
port of [3H]-5FU was expressed as AUC tumor divided by
AUC plasma.
An additional, single HBO exposure group was performed
to elucidate if the generally known enhanced effect of
cytostatic agents in combination with HBO is due to the
high pO2 during and immediately after HBO exposure.
The rats were therefore operated before the single 90 min
HBO exposure, and left to stabilize for 15 min post expo-
sure. 0.2 ml 0.37 MBq [3H]-5FU was injected into the fem-
oral catheter, and dialysate was sampled for the next 70
min, analogue to the standard microdialysis experiments.
Measurement of interstitial fluid pressure (Pif)
Pif was measured using the wick-in-needle (WIN) tech-
nique [7,24]. Briefly, a standard 23-gauge needle, with a 2-
4 mm long sidehole, filled with nylon floss and saline was
inserted into the central part of the tumor and connected
to a transducer dome through a PE-50 catheter. The fluid
communication between the interstitium and the measur-
ing system was confirmed by compression and decom-
pression of the catheter (clamping). This caused a
transient rise and fall in the pressure. A measurement was
accepted when the pressure returned to pre-clamp value
(± 1 mmHg).
Determination of collagen content in the tumors
Hydroxyproline (to estimate collagen content) was deter-
mined in acid hydrolysates of the tumor tissue by a colo-
metric method adapted from Woessner et al. [25].
Oxygen stress measured by Malondialdehyd (MDA)
To evaluate oxidative stress on lipids and membranes (the
status of oxidative damage) we measured the lipid perox-
idation product MDA, in controls and HBO treated
tumors. MDA was analysed by a spectrophotometric assay
according to the manufacturer's protocol (Northwest Life
Science Specialties, LCC, Vancouver). The level of thiobar-
bituric reactive substances (TBARS) was assessed in tissue
homogenates (10% w/v prepared from frozen samples).
As recommended for complex samples, the 3rd-derivative
spectra (400-700 nm) were obtained, and MDA levels
were calculated based on the peak value around 510-520
nm
Volume calculations by the dilution principle
Extracellular volume (ECV) and plasma volume (PV) in
tumor and skin was measured by radioactively labelled
isotopes using the dilution principle as previously
described [26]. Total tissue water (TTW) was calculated as:
(wet weight-dry weight)/(dry weight). Samples were dried
at 50°C until constant weight. The distribution volumes
for  51Cr-EDTA (Institute of Energy Technology, Kjeller,
Norway) and 125I-labeled human serum albumin (125I-
Table 1: The experimental groups.
Experimental groups Gas Ambient pressure pO2 Number of exposures Exposure time
Control air 1 bar 0.2 - -
Repeated HBO treatment O2 2 bar 2.0 4 90 min
Single HBO treatment O2 2 bar 2.0 1 90 minBMC Cancer 2009, 9:446 http://www.biomedcentral.com/1471-2407/9/446
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HSA) (Institute of Energy Technology, Kjeller, Norway),
measuring ECV and PV respectively, were calculated as
plasma equivalent volumes, i.e. counts per min per mg of
tissue divided by counts per min per ml of plasma. Both
isotopes were given after functional nephrectomy by bilat-
eral ligation of the renal pedicles via flank incision. 51Cr-
EDTA (0.7 MBq) was injected into the jugular catheter
and left to circulate for 85 min before injecting 0.05 MBq
125I-HSA. Blood samples were taken 5 min later, by heart
puncture.
Immunohistochemistry
The animals were sacrificed with saturated KCl during
anaesthesia and the tumors were immediately dissected
out and put into liquid N2 and then stored in -80°C.
Frozen tumor sections (20 μm) were used for studying
lymph-vessel morphology. The sections were stained with
an antibody against lymphatic vessel endothelial hyaluro-
nan receptor-1 (LYVE-1) with the Avidin-Biotin Complex
(ABC) method, using a commercially available kit (Vector
Vectastatin Elite ABC Staining Kit, Vector Laboratories
Inc). Diaminobenzidine (DAB) was used as a chromogen
to visualize the lymph-vessels. Finally, the sections were
counterstained with Richardsons dye. The sections were
examined using a Nikon light microscope (THP Eclipse
E600, Nikon Corporation, Tokyo, Japan) and the images
were captured with a Nikon Digital Camera (DXM 1200F,
Nikon Corporation, Tokyo, Japan).
Statistics
All data were tested for normality prior to the choice of
statistical analysis. Results were analysed statistically
using two-way analysis with unpaired t-test comparing
results from the groups. Paired t-test was used when com-
paring results within the same group of animals. Non-par-
ametric Mann-Whitney test was used for the Pif
measurements, while ANOVA with Tukey post test was
used to compare the results from the microdialysis. A
value of p < 0.05 was considered statistically significant.
Results
Dose response of 5FU
To examine if different doses of the chemotherapeutic
drug might influence the effect on tumor growth, dose
response of 3 different doses were tested. However, there
was no significant difference in tumor growth inhibition
between the three different doses of 5FU (Figure 1). (n =
5 for each group).
Uptake of [3H]-5FU
Microdialysis was used to examine if oxygenation of the
tumor after HBO treatment influenced the direct uptake
of the chemotherapeutic drug into the tumor tissue.
Microdialysis showed no increase in uptake of [3H]-5FU
into the tumor tissue 24 hours after the last repeated HBO
treatment (n = 8) compared to control (n = 7). However,
immediately after the single HBO treatment (n = 5) there
was a significant increase in uptake (p < 0.05) (Table 2).
Hyperoxia lowers interstitial fluid pressure (Pif)
As elevated Pif has been proposed to inhibit the transport
and effect of chemotherapy, we wanted to elucidate if this
was the case also for DMBA induced mammary tumors.
The Pif is usually high in solid tumors, reaching 5.5 ± 0.9
mmHg in the control tumors (n = 9) (Table 2). However,
the average Pif after both single (n = 17) and repeated
HBO (n = 13) treatment was significantly reduced (p <
0.05) compared to control.
Hyperoxia influences collagen fibrils
A dense collagen network has been proposed to hinder
efficient transport of chemotherapeutic drugs. Therefore
we have elucidated collagen content in both control and
HBO treated tumors. The amount of hydroxyproline was
significantly lower in the HBO treated tumors compared
to controls, indicating a corresponding decrease in colla-
gen content (Table 2).
Hyperoxia and oxygen radicals
As hyperoxia might induce elevated oxygen radical levels,
it was desirable to measure if this could have influenced
the effect of chemotherapy after HBO treatment. Measure-
ments of MDA-levels showed no significant differences in
oxygen radicals compared to control (n = 5), neither in
the acute (n = 5) nor the repeated (n = 5) HBO treated
group (Table 2). The higher mean value in the repeated
group is due to one diverging value. Discarding this value
would give an identical mean as to the two other groups.
Extracellular fluid volume, plasma volume and total tissue 
water
Since Pif in the HBO treated tumors was lowered, we
assumed that this could influence the fluid distribution.
However, there was no statistically significant difference
in ECV, PV or TTW in either the tumor or skin tissue
between control (n = 9) and repeated HBO treated rats (n
= 8) (Table 3).
Hyperoxia influenced tumor lymphatics
As the amount and functionality of lymph vessels influ-
ence both Pif, fluid distribution and possibly the transport
of chemotherapy, we stained lymph vessels to elucidate
possible changes after HBO. Staining with LYVE-1 showed
continuous lymphatic vessels in the mammary control
tumors, located in the connective tissue close to larger
blood vessels. After HBO treatment, however, the lym-
phatic vessels are disintegrated and no longer continuous
(Figure 2).BMC Cancer 2009, 9:446 http://www.biomedcentral.com/1471-2407/9/446
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Discussion
Stuhr et al. [14] demonstrated increased effect of the com-
monly used cytostatic drug 5FU in DMBA-induced mam-
mary tumors, when injected intraperitoneally
immediately before each HBO treatment. Dose-response
experiments in this study showed no statistical difference
between 1/3×, 1× and 3× dose of 5FU (Figure 1), indicat-
ing that it must be the HBO treatment that potentiated the
effect of the chemotherapeutic drug. We therefore wanted
to investigate if there is an effect of either a single or
repeated treatment of 2 bar pure oxygen on the uptake of
radioactively labelled 5FU in the tumor tissue per se. We
have concluded that the potentiation of the chemothera-
peutic effect after HBO is not only due to an enhanced
cytotoxicity of the tumor cells, as has been previously pos-
tulated in the literature [15,27,28], but also due to an
direct increase in uptake of the chemotherapeutic drug.
Successful delivery of systemically administered cytostatic
agents to the tumor tissue requires that the drug must
reach the target cells in optimal dosage and in addition be
effective in the tumor microenvironment. After a mole-
cule has been moved out of the blood vessels and into the
interstitium, further transport is heavily influenced by the
organization and conductivity, and thereby the composi-
tion of the interstitium. Several investigators have shown
increased uptake of cytostatic agents after decreased
tumor Pif [8,29-32]. In a recent review, Heldin et al. [8]
suggest that increased Pif contributes to a decreased capil-
lary transport in tumors, to hinder efficient uptake of
drugs into the tumor tissue. Additionally, the composi-
tion and organisation of the ECM, cell-cell interactions,
and the tumor structure also affect drug penetration [33].
Eikenes et al. [11] proposed that the structure of the ECM
is the single most important factor for macromolecule
uptake. In accordance with this, Netti et al. [9], found an
unexpected correspondence between transport resistance
and the mechanical stiffness of the ECM, with an
extended collagen network in the more penetration-resist-
ant tumors. Also, others have shown that tumors with
high collagen density and small interstitial space have
lower drug penetration [34,35]. Furthermore, increased
blood flow and blood vessel permeability are factors that
are important in drug-uptake [36]. Thus, we chose espe-
cially to investigate the relation between uptake of the
The effect of three different doses of 5-fluorouracil (5FU) on tumor growth, original dose (1.5 mg/kg), 1/3 (0.5 mg/kg) dose and  3× (4.5 mg/kg) dose Figure 1
The effect of three different doses of 5-fluorouracil (5FU) on tumor growth, original dose (1.5 mg/kg), 1/3 (0.5 
mg/kg) dose and 3× (4.5 mg/kg) dose. Tumor growth is measured as % of initial volume. Mean ± SD.BMC Cancer 2009, 9:446 http://www.biomedcentral.com/1471-2407/9/446
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cytostatic drug, transendothelial transport, tumor Pif and
the collagen fibril network.
We found a significant reduction in tumor Pif after both
acute and repeated HBO treatment, and expected that this
would be reflected in an increased uptake of [3H]-5FU
after both treatments. This is, however, not the fact in our
study, where the uptake of [3H]-5FU was significantly
increased after single HBO treatment, but not after the
repeated HBO treatment. The cpm-ratio between tumor
and plasma was stable over the 70 min sampling-period
during microdialysis for the single HBO treatment, indi-
cating a constant condition determining the uptake. The
increased uptake of the drug into the tumor tissue, after
single HBO exposure is most likely influenced by
increased pO2. Previous studies reported enhanced pO2
for up to one hour after HBO treatment [12,37]. Since the
repeated HBO treated animals were measured 24 hours
after the last HBO treatment, the pO2 is normalized and
any effect of pO2 will not be measurable. In the single
HBO experiments, however, the pO2 is still high. The
repeated HBO treatment probably induces more long-
term changes in the tumor tissue that influences Pif. The
reduction in collagen may be involved in the reduction of
Pif over time. Stromal fibroblasts are able to exert tension
on the collagen microfibrillar network through the colla-
gen binding integrins [38]. When the amount of collagen
fibrils is reduced, as shown with hydroxyproline quantifi-
cation, this effect would not be as pronounced, and the Pif
might be reduced. Thus, it seems like repeated HBO treat-
ment have reduced tumor Pif by reducing collagen content
and density, most likely by enhancing breakdown of col-
lagen.
Tumor vessels are hyperpermeable due to up-regulation of
vascular mediators such as nitric oxide, bradykinin as well
as anatomic defects like large gap junctions between adja-
cent cells and lack of pericytes [36,39]. An explanation for
the lack of uptake of [3H]-5FU in the repeated HBO
treated tumors, might be the proposed mechanism by Lee
et al. [40] of "normalization" of the abnormal structure
and function of the tumor vasculature after anti-ang-
iogenic treatment. We have previously shown that
repeated HBO induces an anti-angiogenic effect in the
DMBA induced tumors [19,21]. Lee et al. [40] suggested
that it is the quality of the vascular organization and not
just the quantity of the vessels that determines the vessel
function, and that the loss of endothelial cells would
reduce the tortuousity of vessels or eliminate them alto-
gether. Later, several preclinical and clinical studies
[41,42] have shown that the "normalized" vasculature
after anti-angiogenic therapy had less leaky and tortuous
vessels, with more normal basement membranes and bet-
ter pericyte coverage, and that these structural changes
Table 2: Uptake of [3H]-5-fluorouracil (5FU), interstitial fluid pressure (Pif), collagen content and malondialdehyd (MDA) levels in 
controls and after repeated or single hyperbaric oxygen exposure (HBO).
Control Repeated HBO Single HBO
Uptake of [3H]-5FU
(AUC tumor/AUC plasma)
0.17 ± 0.12
(n = 7)
0.20 ± 0.11
(n = 8)
0.42 ± 0.21 *
(n = 5)
Pif
(mmHg)
5.5 ± 2.6
(n = 9)
2.3 ± 2.7*
(n = 11)
2.5 ± 2.9*
(n = 17)
%collagen of dry weight 11.6 ± 5.0
(n = 6)
5.0 ± 1.1*
(n = 4)
MDA levels
(nmol/mg prot)
0.09 ± 0.01
(n = 5)
0.15 ± 0.11
(n = 5)
0.09 ± 0.02
(n = 5)
Mean ± SD.
* p < 0.05 vs control
Table 3: The extracellular volume (ECV), plasma volume (PV) and total tissue water (TTW) in skin and tumor in control and after 
repeated hyperbaric oxygen (HBO) exposure. 
ECV
(ml/g dry weight)
PV
(ml/g dry weight)
TTW
(ml/g dry weight)
Skin Tumor Skin Tumor Skin Tumor
Control
(n = 9)
0.55 ± 0.12 1.00 ± 0.27 0.007 ± 0.004 0.07 ± 0.04 1.44 ± 0.09 3.73 ± 0.45
HBO
(n = 8)
0.50 ± 0.18 0.85 ± 0.47 0.004 ± 0.003 0.06 ± 0.03 1.45 ± 0.2 4.05 ± 0.9
Means ± SD.BMC Cancer 2009, 9:446 http://www.biomedcentral.com/1471-2407/9/446
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were accompanied by "normalization" of the tumor
microenvironment. This modification in vascular archi-
tecture would decrease vascular permeability and reduce
flow resistance and hence lower both mean venous pres-
sure and Pif [8]. Experimental studies have demonstrated
that anti-angiogenic therapy can decrease the overall dis-
tribution of large macromolecules such as antibodies for
instance [43,44] and decrease blood perfusion [45]. Thus,
since we have previously shown that HBO has an anti-
angiogenic effect on DMBA induced tumors after repeated
HBO treatment [19], this will together with a possible
reduced capillary permeability, impede transendothelial
transport of [3H]-5FU, even though Pif is lowered.
In normal tissue, the interstitial fluid volume is kept fairly
constant by several mechanisms [46], such as lymph flow
and adjustment of pressures acting across the capillary
wall [47]. LYVE-1 surprisingly shows continuous lymph
vessels in our control tumors, but dissolved lymph vessels
after repeated HBO treatment. However, Fukumura et al.
[48] stated that even though the structures with lymphatic
endothelial marker are present in tumors, they probably
do not transport fluid or macromolecules. This, together
with the observed lowering of tumor Pif after repeated
HBO treatment, should lead to an increase in ECV. Never-
theless, ECV, PV and TTW did not change in tumors after
repeated HBO treatment compared to control, indicating
that neither the lowered Pif nor the disintegrated lymphat-
ics after HBO contribute to the unchanged ECV found in
Lymph vessels stained with LYVE-1 in two different control tumors (A and C) and hyperbaric oxygen (HBO) treated tumors (B  and D) Figure 2
Lymph vessels stained with LYVE-1 in two different control tumors (A and C) and hyperbaric oxygen (HBO) 
treated tumors (B and D). The staining was performed concomitant in the two groups. Note disintegration of lymphatics 
after HBO treatment, and seemingly anatomically normal lymphatics in untreated control tumors.BMC Cancer 2009, 9:446 http://www.biomedcentral.com/1471-2407/9/446
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the present study. As already mentioned, the possible
"normalization" of the tumor vasculature, after repeated
HBO treatment, is expected to normalize capillary perme-
ability, and thereby prevent any increase in ECV, even
though Pif is decreased.
Reactive oxygen species and oxidative stress are consid-
ered to be important in several aspects of malignancies,
both in tumor development as well as therapeutic strate-
gies such as radiotherapy [49]. Since changes in oxygen
concentration may affect the production of its reactive
derivatives in the tumor, it is relevant to suggest that anti-
tumor effects of HBO may be due to oxidative stress. Fur-
thermore, as stated in the introduction, some
chemotherapeutic drugs require oxygen to generate free
radicals that induce cytotoxicity. However, our measure-
ments of lipid peroixidation (MDA) did not indicate any
significant effect on the oxidative status of the tumor tis-
sue. Oxidative stress is therefore not likely to be involved
in the potentiated effect of 5FU after HBO.
Most solid tumors depend on increased rates of glycolysis
to satisfy their energy demand [50]. This leads to
decreased pH in the tumor microenvironment due to
excessive lactate secretion. Hyperoxic treatment enhances
oxygenation of the tumor tissue, and may therefore pro-
mote a reversion from the anaerobic metabolism back to
non-tumorigentic, oxidative metabolism and thereby
increased pH [21]. A less acidic microenvironment may
therefore have a positive effect on the cytotoxicity of
chemotherapy. However, although increased cytotoxicity
has previously been postulated to be the main determi-
nant of the enhanced effect of chemotherapy after HBO
treatment in addition to enhanced neovascularisation, the
present study has shown that it is also due to an active
uptake of the drug into the tumor tissue.
In conclusion, we showed that hyperoxia increases the
uptake of [3H]-5FU in DMBA-induced mammary tumors,
independently of changes in Pif, collagen fibril density, or
transendothelial transport alone, as one could expect
from the literature. The mechanism by which such an
uptake occurs is clearly stimulated by elevated pO2, but
still not elucidated.
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